Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Increased by Thompson Investment Management Inc.

Thompson Investment Management Inc. raised its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.3% in the first quarter, HoldingsChannel reports. The institutional investor owned 6,670 shares of the specialty pharmaceutical company’s stock after purchasing an additional 150 shares during the quarter. Thompson Investment Management Inc.’s holdings in Jazz Pharmaceuticals were worth $803,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Baupost Group LLC MA lifted its position in Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock worth $102,545,000 after buying an additional 160,000 shares in the last quarter. Polaris Capital Management LLC lifted its position in Jazz Pharmaceuticals by 2.2% in the 4th quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock worth $155,898,000 after buying an additional 27,100 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $380,000. International Assets Investment Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at $7,201,000. Finally, Desjardins Global Asset Management Inc. acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at $1,943,000. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Trading Down 1.6 %

Shares of JAZZ traded down $1.75 on Tuesday, reaching $108.08. 668,106 shares of the company’s stock were exchanged, compared to its average volume of 696,758. The stock has a market capitalization of $6.82 billion, a P/E ratio of 22.65, a price-to-earnings-growth ratio of 1.66 and a beta of 0.62. The business has a 50 day moving average price of $109.06 and a two-hundred day moving average price of $117.10. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. Jazz Pharmaceuticals plc has a 12 month low of $103.01 and a 12 month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The firm had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. Research analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on JAZZ. Barclays decreased their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. Needham & Company LLC decreased their target price on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating on the stock in a research report on Thursday, June 20th. Stifel Nicolaus lifted their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research report on Friday, March 15th. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $190.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.